Occurrence of sleep-related breathing disorders in patients with chronic urticaria at its asymptomatic or oligosymptomatic stages

Postepy Dermatologii i Alergologii

Volumn 33, Issue 1, 2016, Pages 63-67

  Perkowska, Jolanta ^a   Kruszewski, Jerzy ^a   Gutkowski, Piotr ^a   Chcialowski, Andrzej ^a   Klos, Krzysztof ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Chronic urticaria; CU Q2oL; Quality of life; Respiratory polygraphy; Sleep related breathing disorders

Indexed keywords

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BREATHING DISORDER; CHRONIC URTICARIA; CHRONIC URTICARIA QUALITY OF LIFE QUESTIONNAIRE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONCENTRATION PROCESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; FEMALE; HUMAN; INCIDENCE; MALE; MULTICHANNEL RECORDER; POPULATION; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; QUESTIONNAIRE; SKIN DISEASE ASSESSMENT; SLEEP DISORDER; SLEEP RELATED BREATHING DISORDER; SYMPTOM ASSESSMENT;

EID: 84959931362     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: 10.5114/pdia.2015.48052     Document Type: Article

References (26)

1. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999; 140: 667-71.
2. Zelazny I, Nowicki R, Majkowicz M, et al. Jakosc zycia w chorobach skóry. Przew Lek 2004; 9: 60-5.
3. Finlay A. Research methodology in quality of life assessment. In: Psychodermatology: The psychological impact of skin disorders. Walker C, Papadopoulos L (eds.). Cambridge University Press, Cambridge 2005; 116-30.
4. Ucmak D, Akkurt M, Toprak G, et al. Determination of dermatology life quality index, and serum C-reactive protein and plasma interleukin-6 levels in patients with chronic urticarial. Adv Dermatol Allergol 2013; 3: 146-51.
5. Tyc-Zdrojewska E, Trznadel-Grodzka E, Kaszuba A. Wplyw przewleklych chorób skóry na jakosc zycia pacjentów. Dermatol Klin 2011; 13: 155-60.
6. Kiec-Swierczynska M, Krecisz B, Potocka A, et al. Czynniki psychologiczne w przebiegu chorób alergicznych skóry. Med Pr 2008; 59: 279-85.
7. Brzoza Z. Jakosc zycia i zaburzenia psychiczne u chorych na przewlekla pokrzywke. Przew Lek 2012; 2: 16-7.
8. Zuberbier T, Asero R, Bindslev-Jansen C, et al. EAACI/GA- 2LEN/EDF/WAO Guideline for the definitions, classification, diagnosis and management of urticarial: The 2013 revision and update. Allergy 2009; 64: 1417-26.
9. Glinski W, Silny W, Czarnecka-Operacz M, et al. Postepowanie diagnostyczno-lecznicze w pokrzywce. Konsensus zespolu specjalistów w dziedzinie dermatologii i wenerologii oraz alergologii. Adv Dermatol Allergol 2007; 24: 1-10.
10. Brzoza Z, Badura-Brzoza K, Mlynek A, et al. Adaptation and initial results of the Polish version of the GA(2)LEN chronic urticaria quality of life questionnaire (CU-Q(2)oL). J Dermatol Sci 2011; 62: 36-41.
11. Plywaczewski R, Brzecka A, Bielicki P, et al. Zalecenia Polskiego Towarzystwa Chorób Pluc dotyczace rozpoznawania i leczenia zaburzen oddychania w czasie snu (ZOCS) u doroslych. Pneumonol Alergol Pol 2013; 81: 221-58.
12. Chazan R. Klasyfikacja, obraz kliniczny i diagnostyka zaburzen oddychania w czasie snu. Pneumonol Alergol Pol 2007; 75 (Suppl. 1): 15-9.
13. American Academy of Sleep Medicine - The International Classification of Sleep Disorders. Revised. Diagnostic and Coding Manual. American Academy Sleep Medicine 2005; 1-401.
14. Plywaczewski R. Czestosc i nasilenie zaburzen oddychania w czasie snu wsród doroslej populacji prawobrzeznej Warszawy. Instytut Gruzlicy i Chorób Pluc, Warsaw 2003; 1-291.
15. Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: Chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy 2005; 60: 1073-8.
16. Jaeschke R, Guyatt GH, Cook D, Miller J. Okreslanie i mierzenie jakosci zycia zwiazanej ze zdrowiem. Med Prakt 1999; 3016: 155-62.
17. Ware JE, Sherbourne CD. The MOS 36-item short-form Health Survey (SF36). Conceptual framework and item selection. Med Care 1992; 30: 437-83.
18. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - A simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6.
19. Szepietowski J, Salomon J, Finlay AY, et al. DLQI: Polish version. Dermatol Klin 2004; 6: 63-70.
20. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1997; 37: 41-50.
21. Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of life measure for patients with skin disease: Reliability, validity and responsiveness. J Invest Dermatol 1996; 107: 707-13.
22. Maurer M, Magerl M, Metz M, Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges 2013; 11: 971-8.
23. Thakkar MM. Histamine in the regulation of wakefulness. Sleep Med Rev 2011; 15: 65-74.
24. Kano M, Fukudo S, Tashiro A, et al. Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci 2004; 20: 803-10.
25. Belsito DV. Second-generation antihistamines for the treatment of chronic idiopathic urticaria. J Drugs Dermatol 2010; 9: 503-12.
26. Wrona D, Jurkowski KJ, Bobek-Nillewicz B, et al. Neurotransmitery i neuromodulatory snu. Sen 2005; 5: 56-64.